# Empirico

**Canonical:** https://apis.io/providers/empirico/  
**Website:** https://www.empiri.co/  
**APIs profiled:** 0

Empirico is a biotechnology company that powers therapeutic discovery with human genetics and small interfering RNA (siRNA) medicines. Combining internal capabilities in human genetics and siRNA chemistry with partner expertise, the company identifies naturally occurring genetic variations associated with health benefits and develops precision oligonucleotide therapeutics for common diseases with significant unmet medical need. In October 2024 Empirico entered a licensing agreement with GSK worth up to $745 million for a clinical-stage oligonucleotide targeting respiratory disease (COPD). Empirico is backed by DCVC. It is a pharmaceutical R&D company and does not operate a public technology or API platform.

## Kin Score — 7.9 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 7.9).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 21.1 |
| Access Clarity | 21.1 |

Regulatory layer — **Health**: 10.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Pharmaceuticals, Drug Discovery, Human Genetics, siRNA, Therapeutics, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/empirico/). Scores are computed from the provider's own public artifacts under a published rubric.